Background The aim of this study was to assess efficacy and safety of saxagliptin
monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and …

Aim: Enhancing the physiologic actions of the endogenous incretin hormones, glucagon‐
like peptide‐1 and glucose‐dependent insulinotropic polypeptide, by inhibiting dipeptidyl …

Background Achievement of glycemic control is an important objective in the management of
type 2 diabetes mellitus (T2DM). Objective The objective of this study was to evaluate the …

Saxagliptin (Onglyza®) is a highly potent, reversible, competitive dipeptidyl peptidase-4
inhibitor indicated for the treatment of patients with type 2 diabetes. Numerous well …

Purpose The pharmacology, pharmacokinetics, efficacy, safety, and dosage and
administration of saxagliptin are reviewed. Summary Saxagliptin is a selective, reversible …

ABSTRACT Introduction: Dipeptide peptidase-4 (DPP-4) inhibitors such as saxagliptin are
established and efficacious oral therapies in the management of type 2 diabetes. These …

Objective: To evaluate the efficacy and safety of once-daily saxagliptin monotherapy in
treatment-naïve patients with type 2 diabetes (T2D) and inadequate glycemic control …

Background Few studies have assessed the use of new oral anti‐diabetic agents in Asian
populations. This study assesses the efficacy and safety of saxagliptin versus placebo in …

Saxagliptin (Onglyza™) is a dipeptidyl peptidase 4 inhibitor widely approved for the
treatment of type 2 diabetes mellitus. In the EU, saxagliptin is indicated as combination …

Background: The mechanism of action of dipeptidyl peptidase-4 inhibitors, such as
saxagliptin, makes them suitable for combination therapy in type 2 diabetes mellitus (T2DM) …